CANSINOBIO (06185.HK) will release its Earnings Reports on April 29.

$CANSINOBIO (06185.HK) will release its Earnings Reports on April 29, and investors are advised to pay attention. How was the previous performance? 2024 Q1 revenue was 0.114 billion yuan, Net income was -0.175 billion yuan, and EPS was -0.69 yuan. Futubull reminder: 1. There are no strict regulations on the accounting year division time for Hong Kong and U.S. listed companies; it is entirely decided by the company itself. Therefore, each Earnings Reports period can be treated as the company's annual report deadline, rather than following the natural year as the fiscal year. 2. Generally, the company will hold an Earnings Reports meeting on or around the date of the aforementioned Earnings Reports release.

Moomoo NewsApr 22 21:00 ET

CANSINOBIO: 2024 ANNUAL REPORT

HKEXApr 16 08:43 ET · Announcements

CANSINOBIO (06185.HK) plans to hold a Board of Directors meeting on April 29 to approve the first quarter performance.

On April 15, Gelonghui reported that CANSINOBIO (06185.HK) announced that the Board of Directors meeting will be held on April 29, 2025 (Tuesday) to consider and approve the first quarter performance of the company and its subsidiaries for the three months ending March 31, 2025, and its release.

Gelonghui FinanceApr 15 04:50 ET

[Brokerage Focus] FIRST SHANGHAI gives CANSINOBIO (06185) a Buy rating, expecting the company to achieve breakeven by 2025.

Jingwu Finance | FIRST SHANGHAI's Research Reports indicate that CANSINOBIO (06185) achieved revenue of 0.825 billion yuan in 2024 (up 139.0% year-on-year, the same below). After excluding the estimated impact of returns on the COVID-19 vaccine, the year-on-year growth is 37.9%. Among them, MCV products continue to experience rapid growth, with annual revenue of 0.794 billion yuan, representing a year-on-year increase of 41%. The company's total selling expenses for the year amounted to 0.369 billion yuan (+0.3%), management expenses were 0.194 billion yuan (-34.0%), and R&D expenses were 0.416 billion yuan (-34.8%). Both management expenses and R&D expenditures have significantly decreased, reflecting effective cost control.

Jinwu Financial NewsApr 14 05:19 ET

[Brokerage Focus] China Securities Co., Ltd. is Bullish on the Innovative Drugs Industry which is currently not affected by tariffs.

Jinwu Financial News | China Securities Co.,Ltd. stated that the impact of tariff policies on the Pharmaceutical Industry Chain is quite complex and may still have uncertainties. In the recent tariffs imposed by the USA on China, Pharmaceuticals are not currently involved. At this point, the firm is Bullish on the Innovative Drugs sector, the opportunities for domestic share increases in Medical Devices and Blood Products under autonomous control, and the Traditional Chinese Medicine, pharmacies, and distribution sectors focused on domestic demand, which are not significantly affected by tariffs. In the long run, going abroad should still be an important Global Strategy for pharmaceutical companies, and the firm firmly believes in the incremental opportunities brought by overseas expansion. The firm pointed out that 1) Innovative Drugs: Currently, going overseas mainly involves BD collaborations.

Financial NewsApr 6 20:42 ET

Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.

① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.

cls.cnApr 1 03:04 ET